CAS: 136293-03-3

41-Oxo-rapamycin is a synthetic derivative of rapamycin, which is a macrocyclic lactone. It is derived from Streptomyces hygroscopicus, a gram-positive bacterium known for producing various bioactive compounds. The mode of action of 41-Oxo-rapamycin involves binding to the FK506-binding protein (FKBP12), forming a complex that subsequently inhibits the mammalian target of rapamycin (mTOR) pathway. This inhibition results in the suppression of T-cell proliferation and modulation of immune responses. The compound is primarily used in research settings to explore its potential applications in immunosuppressive therapies and organ transplantation. It is also a valuable tool for investigating the mTOR signaling pathway in cancer research, as it has implications in controlling cell growth and proliferation. Moreover, its role in metabolic regulation and potential neuroprotective effects are topics of ongoing study, providing insights into therapeutic approaches for various diseases, including neurodegenerative disorders and metabolic syndromes.